IMICILA

This brand name is authorized in Nigeria. It is also authorized in Hong Kong SAR China.

Active ingredients

The drug IMICILA contains a combination of these active pharmaceutical ingredients (APIs):

1	Cilastatin UNII 5428WXZ74M - CILASTATIN SODIUM
	Read more about Cilastatin
2	Imipemide UNII 71OTZ9ZE0A - IMIPENEM
	Imipenem is a semi-synthetic derivative of thienamycin, the parent compound produced by the filamentous bacterium Streptomyces cattleya. Imipenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).
	Read more about Imipemide

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-9367	Powder for injection	Imicila Injection INJ_PWD 500 mg; 500 mg	Powder for solution for injection in a vial Each vial contains: Imipenem 500 mg, and Cilastatin Sodium equiv. to Cilastatin 500 mg	20/12/2019

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01DH51	Imipenem and enzyme inhibitor	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DH Carbapenems
Discover more medicines within J01DH51

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
HK	Department of Health Drug Office	64336
NG	Registered Drug Product Database	B4-9367